Cargando…

Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial

AIMS: The effects of serelaxin, a recombinant form of human relaxin-2 peptide, on vascular function in the coronary microvascular and systemic macrovascular circulation remain largely unknown. This mechanistic, clinical study assessed the effects of serelaxin on myocardial perfusion, aortic stiffnes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Corcoran, David, Radjenovic, Aleksandra, Mordi, Ify R, Nazir, Sheraz A, Wilson, Simon J, Hinder, Markus, Yates, Denise P, Machineni, Surendra, Alcantara, Jose, Prescott, Margaret F, Gugliotta, Barbara, Pang, Yinuo, Tzemos, Niko, Semple, Scott I, Newby, David E, McCann, Gerry P, Squire, Iain, Berry, Colin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797213/ https://www.ncbi.nlm.nih.gov/pubmed/32065620 http://dx.doi.org/10.1093/cvr/cvz345

Ejemplares similares

Pharmacokinetics of serelaxin in patients with severe renal impairment or end‐stage renal disease requiring hemodialysis: A single‐dose, open‐label, parallel‐group study
por: Dahlke, Marion, et al.
Publicado: (2015)

Bicuspid Aortic Valve Disease: A Comprehensive Review
por: Mordi, Ify, et al.
Publicado: (2012)

The combined incremental prognostic value of left ventricular ejection fraction, late gadolinium enhancement and global circumferential strain assessed by cardiovascular magnetic resonance
por: Mordi, Ify, et al.
Publicado: (2015)

Utility of Native T1 mapping to differentiate between athlete's heart and non-ischemic dilated cardiomyopathy
por: Mordi, Ify, et al.
Publicado: (2015)

Prevalence and extent of infarct and microvascular obstruction following a range of reperfusion techniques in ST-elevation myocardial infarction
por: Khan, Jamal N, et al.
Publicado: (2013)

Prognostic significance of infarct core pathology in ST-elevation myocardial infarction survivors revealed by quantitative T2-weighted cardiac magnetic resonance
por: Carrick, David, et al.
Publicado: (2015)

Prognostic significance of infarct core pathology in ST-elevation myocardial infarction survivors revealed by non-contrast T1 mapping cardiac magnetic resonance
por: Carrick, David, et al.
Publicado: (2015)

Prognostic significance of quantitative measures of myocardial infarct pathology using native T1 mapping, in survivors of ST-elevation myocardial infarction
por: Carrick, David, et al.
Publicado: (2015)

Pathophysiology of myocardial remodeling in survivors of ST-elevation myocardial infarction revealed by native T1 mapping: inflammation, remote myocardium and prognostic significance
por: Carrick, David, et al.
Publicado: (2015)

Inter-study repeatability of circumferential strain and diastolic strain rate by CMR tagging, feature tracking and tissue tracking in ST-segment elevation myocardial infarction
por: Nazir, Sheraz A., et al.
Publicado: (2020)

Differences in the renal antifibrotic signaling of serelaxin and zaprinast
por: Wetzl, Veronika, et al.
Publicado: (2015)

Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors
por: Carrick, David, et al.
Publicado: (2016)

Prevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in ST-elevation myocardial infarction
por: Khan, Jamal N, et al.
Publicado: (2014)

The many faces of HFPEF: insights from the CMR substudy of DIAMOND-HFPEF
por: Kanagala, Prathap, et al.
Publicado: (2015)

Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats
por: Wang, Dong, et al.
Publicado: (2017)

Pathophysiology of LV Remodeling in Survivors of STEMI: Inflammation, Remote Myocardium, and Prognosis
por: Carrick, David, et al.
Publicado: (2015)

Non-Invasive Imaging in Diabetic Cardiomyopathy
por: Mordi, Ify R.
Publicado: (2019)

Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF
por: Liu, Licette C. Y., et al.
Publicado: (2016)

Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial
por: Snowdon, Victoria K., et al.
Publicado: (2017)

Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-Mediated Airway Relaxation
por: Lam, Maggie, et al.
Publicado: (2016)

Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis
por: Bennett, Robert G, et al.
Publicado: (2017)

Serelaxin Alleviates Fibrosis in Thyroid-Associated Ophthalmopathy via the Notch Pathway
por: Sun, Anqi, et al.
Publicado: (2023)

Inter-study reproducibility of circumferential strain and strain rates at 1.5T and 3T: a comparison of tagging and feature tracking
por: Singh, Anvesha, et al.
Publicado: (2014)

Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure
por: Beldhuis, I. E., et al.
Publicado: (2023)

Comparison of cardiovascular magnetic resonance feature tracking and tagging for the assessment of left ventricular systolic strain in acute myocardial infarction
por: Khan, Jamal N, et al.
Publicado: (2015)

Comparison of T1-mapping and T2-weighted imaging for diagnostic oedema assessment in ST-segment elevation myocardial infarction
por: Nazir, Sheraz A, et al.
Publicado: (2016)

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
por: Metra, Marco, et al.
Publicado: (2013)

Effect of late sodium current inhibition on MRI measured diastolic dysfunction and myocardial perfusion reserve in aortic stenosis: a pilot study
por: Singh, Anvesha, et al.
Publicado: (2015)

Larger infarct size associated with dysglycemia at the time of ST-elevation myocardial infarction is related to later presentation
por: Razvi, Naveed, et al.
Publicado: (2013)

Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2015)

Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection
por: Díez, Javier, et al.
Publicado: (2016)

Protection from cigarette smoke‐induced vascular injury by recombinant human relaxin‐2 (serelaxin)
por: Pini, Alessandro, et al.
Publicado: (2016)

Serelaxin Treatment Reduces Oxidative Stress and Increases Aldehyde Dehydrogenase-2 to Attenuate Nitrate Tolerance
por: Leo, Chen Huei, et al.
Publicado: (2017)

Involvement of Cyclic Guanosine Monophosphate-Dependent Protein Kinase I in Renal Antifibrotic Effects of Serelaxin
por: Wetzl, Veronika, et al.
Publicado: (2016)

Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy
por: Nonhoff, Justus, et al.
Publicado: (2017)

A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)
por: Gifford, Fiona J., et al.
Publicado: (2020)

Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1
por: Wilhelmi, Tim, et al.
Publicado: (2020)

Assessment of stunned and viable myocardium using manganese-enhanced MRI
por: Spath, Nick B, et al.
Publicado: (2021)

Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure
por: Steggall, Abbey, et al.
Publicado: (2017)

Serelaxin: A Novel Therapy for Acute Heart Failure with a Range of Hemodynamic and Non-Hemodynamic Actions
por: Díez, Javier
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mcdpvqhnshma9o8cb4t4klmsi1